The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under President Donald Trump's administration following criticism from the pharmaceutical industry for the Biden-era law.

The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process of negotiating prices for certain Medicare Part D drugs with input f | The agency said it is "considering opportunities to bring greater transparency" and will consider stakeholder feedback on the program.

Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.

The U.S. government said on Wednesday it will consider opportunities to "bring greater transparency" for the Medicare drug price negotiation program under President Donald Trump's administration. The price negotiation process was established under former President Joe Biden's signature Inflation Reduction Act in 2022.

Through the issuance of Inauguration Day executive orders, the Trump Administration signaled its apparent intent to tackle drug pricing reforms

The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.

A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more transparent.